Nissay Asset Management Corp Japan ADV Cuts Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Nissay Asset Management Corp Japan ADV reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 306,720 shares of the company’s stock after selling 1,551 shares during the quarter. Nissay Asset Management Corp Japan ADV’s holdings in Johnson & Johnson were worth $44,490,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Fulcrum Capital LLC lifted its stake in shares of Johnson & Johnson by 6.9% during the 4th quarter. Fulcrum Capital LLC now owns 3,952 shares of the company’s stock worth $572,000 after purchasing an additional 254 shares during the period. Marshall & Sullivan Inc. WA lifted its stake in shares of Johnson & Johnson by 1.6% during the 4th quarter. Marshall & Sullivan Inc. WA now owns 30,155 shares of the company’s stock worth $4,361,000 after purchasing an additional 474 shares during the period. Elevated Capital Advisors LLC lifted its stake in shares of Johnson & Johnson by 33.3% during the 4th quarter. Elevated Capital Advisors LLC now owns 4,978 shares of the company’s stock worth $720,000 after purchasing an additional 1,244 shares during the period. Davis Investment Partners LLC boosted its holdings in shares of Johnson & Johnson by 31.6% in the 4th quarter. Davis Investment Partners LLC now owns 4,103 shares of the company’s stock valued at $583,000 after purchasing an additional 985 shares during the last quarter. Finally, Sunflower Bank N.A. boosted its holdings in shares of Johnson & Johnson by 2.4% in the 4th quarter. Sunflower Bank N.A. now owns 10,572 shares of the company’s stock valued at $1,529,000 after purchasing an additional 244 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Down 3.5%

JNJ stock opened at $148.71 on Wednesday. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The company’s 50 day simple moving average is $157.33 and its 200-day simple moving average is $154.14. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The firm has a market capitalization of $357.81 billion, a P/E ratio of 22.36, a P/E/G ratio of 2.56 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.59 by $0.18. The company had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be paid a dividend of $1.30 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a yield of 3.50%. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson’s dividend payout ratio is presently 57.84%.

Insider Activity at Johnson & Johnson

In other news, EVP Timothy Schmid sold 403 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. This represents a 2.60% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Robert J. Decker sold 6,999 shares of the stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the transaction, the vice president now owns 21,001 shares of the company’s stock, valued at approximately $3,483,645.88. This represents a 25.00% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $181.00 price target on shares of Johnson & Johnson in a report on Wednesday, April 16th. The Goldman Sachs Group upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their price target for the company from $157.00 to $172.00 in a report on Wednesday, April 9th. Morgan Stanley lifted their price target on shares of Johnson & Johnson from $164.00 to $169.00 and gave the company an “equal weight” rating in a report on Wednesday, April 16th. Bank of America cut their target price on shares of Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating on the stock in a research note on Thursday, April 10th. Finally, Wells Fargo & Company cut their target price on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Ten equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $170.88.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.